Standard treatment for metastatic prostate cancer, with or without local treatment
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer proven by biopsy or surgical sample as adenocarcinoma (not pure small cell, sarcomatoid, or squamous types).
- Your prostate is still in place, and you have not had prior prostate-focused treatments like ablation or brachytherapy.
- Your cancer has spread to bones and other places based on standard scans (bone scan plus CT or MRI) within the last 42 days, and there is no brain spread.
- You’ve already had 22–28 weeks of standard hormone-based treatment (or surgical castration) and your cancer has not progressed during that time.
- You’re not planning to start docetaxel after joining the study, and side effects from prior treatment are mostly mild or gone (no worse than mild).
- You must have recent PSA and testosterone blood tests, and be well enough to do most normal activities (Zubrod performance status 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
This trial tests whether using a special PET scan (FDG-PET) to find and treat only the spots where cancer has spread with targeted radiation can help men with prostate cancer that has spread but still responds to hormone therapy. It compares standard treatment alone to standard treatment plus this targeted radiation.
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
This study tests adding a targeted local treatment (like radiation or surgery) to standard hormone therapy for men with advanced prostate cancer that still shows up on a special scan. The goal is to see if this combination helps control the cancer better.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
Hear when a new Stage IV Prostate Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.